Everything you need to know about Expanded Access; October 5th, 4pm Eastern

Monday, October 5th, 4pm-5pm Eastern
Expanded Access:
the history, regulation, and best practices
An educational webinar for drug developers and clinics
By ALS Emergency Treatment Fund and the ALS Association:

Recent activism, old narratives, and newcomer journalists have generated a lot of confusion about early access to new medical treatments.    To truly assess the feasibility of access programs in diseases like ALS, a serious review of the facts is necessary.

Join us at 4pm Eastern, Monday, October 5th for our presentation of Expanded Access in the United States.

Areas to be covered:
  • The Treatment IND:   large, protocol-driven "treatment-use" trials
  • FDA-authorized Expanded Access vs. state-level initiatives
  • Ensuring harmony and non-interference with research trials
  • Reimbursement, cost sharing, and community support
Jess Rabourn, Chartered Financial Analyst

Jess is the founder of ALS Emergency Treatment Fund, a non-profit specialty platform for sponsoring group-level Expanded Access programs in collaboration with drug companies and trial sites.    He has given 15 public talks on Expanded Access and has published relevant papers in the American Journal of Bioethics and Clinical Trials Arena.
Register for the Webinar

Please RSVP to [email protected], with "EA Webinar" on the Subject Line.   Be sure to include your name, title, and contact information.

You will receive confirmation and login instructions.

STAY CONNECTED: